0000921114 false 0000921114 2022-08-11 2022-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, DC 20549






Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of report (Date of earliest event reported): August 11, 2022



(Exact name of Registrant as specified in its charter)


Washington 001-37544 91-1549568
(State or other jurisdiction of
incorporation or organization)
(Commission File Number) (IRS Employer Identification No.)


4503 Glencoe Avenue

Marina del Rey, California



(Address of principal executive offices) (Zip Code)


(310) 655-2928

(Registrant’s Telephone number)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨


Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered
Common Stock   ARMP   NYSE American







Item 2.02 Results of Operations and Financial Condition.


On August 11, 2022, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2022, in the press release furnished hereto as Exhibit 99.1.


The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits.





99.1   Press Release, dated August 11, 2022.
104   Cover Page Interactive Data File (embedded within Inline XBRL document).







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: August 11, 2022 Armata Pharmaceuticals, Inc.
  By: /s/ Erin Butler
  Name: Erin Butler
  Title: Vice President, Finance & Administration




EX-99.1 2 tm2223185d1_ex99-1.htm EXHIBIT 99.1


Exhibit 99.1



Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update


MARINA DEL REY, Calif., August 11, 2022 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter 2022 and provided a corporate update.


Second Quarter 2022 and Recent Developments:


·AP-PA02 advancing through final MAD cohort of SWARM-P.a. trial


·Phase 2 Tailwind study of AP-PA02 in non-CF bronchiectasis (NCFB) initiated


·AP-SA02 Phase 1b/2a Staphylococcus aureus bacteremia study (‘diSArm’) actively enrolling


·Pipeline expansion continues with IND approval for AP-SA02 in prosthetic joint infection


·Engineered, second generation AP-PA02 therapeutic candidate selected


·Continued investment in manufacturing capabilities


“During the second quarter, we continued to advance our portfolio of innovative bacteriophage therapeutics. We now have four approved INDs, positioning Armata to robustly evaluate bacteriophage effectiveness in difficult-to-treat infections," stated Dr. Brian Varnum, Chief Executive Officer of Armata. “At the same time, we continued to advance the science of bacteriophage. Armata’s synthetic biologists have engineered a second-generation AP-PA02 product with improved pharmacological properties. Additionally, significant improvements in manufacturing processes have resulted in improved yield and purity, with methods that are readily scalable. These methods lay the groundwork for the next phase of Armata’s growth as we build out our new 56,000 square foot facility.”


Second Quarter 2022 Financial Results:


Grant Revenue. The Company recognized grant revenue of approximately $1.9 million for the three months ended June 30, 2022, which represents Medical Technology Enterprise Consortium’s (“MTEC”) share of the costs incurred for the Company’s AP-SA02 program for the treatment of Staphylococcus aureus bacteremia. The Company expects to receive $15.0 million in grant funding from MTEC administered by the U.S. Department of Defense and the Defense Health Agency and Joint Warfighter Medical Research Program. The Company recognized approximately $1.2 million of revenue in the comparable period in 2021.


Research and Development. Research and development expenses for the three months ended June 30, 2022, were approximately $9.0 million as compared to approximately $5.2 million for the comparable period in 2021. The Company continues to invest in clinical trial and personnel related expenses associated with its primary development programs.


General and Administrative. General and administrative expenses for the three months ended June 30, 2022, were approximately $2.1 million as compared to approximately $2.1 million for the comparable period in 2021.


Loss from Operations. Loss from operations for the three months ended June 30, 2022, was $(9.2) million as compared to a loss from operations of approximately $(6.2) million for the comparable period in 2021.


Cash and Equivalents. As of June 30, 2022, Armata held approximately $37.0 million of unrestricted cash and cash equivalents, as compared to $10.3 million as of December 31, 2021.






As of August 9, 2022, there were approximately 36.1 million shares of the Company’s common stock outstanding.


About Armata Pharmaceuticals, Inc.


Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.


Forward Looking Statements


This communication contains "forward-looking" statements, including, without limitation, statements related to the use of proceeds from the securities offering, Armata's bacteriophage development programs,  Armata's ability to meet expected milestones, Armata's ability to be a leader in the development of phage-based therapeutics, Armata’s expectations regarding receiving future grant funding and statements related to the timing and results of clinical trials, including the anticipated initiation and advancement of clinical trials of AP-PA02 and AP-SA02, Armata's ability to develop new products based on bacteriophages and synthetic phages, and Armata's expectations for performance of Armata's therapeutic candidates based on Armata's recent nonclinical work. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Armata's current expectations. Forward-looking statements involve risks and uncertainties. Armata's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the ability of Armata's lead clinical candidates, AP-PA02 and AP-SA02, to be more effective than previous candidates; Armata's ability to expedite development of AP-PA02 and AP-SA02; Armata's ability to advance its preclinical and clinical programs and the uncertain and time-consuming regulatory approval process; Armata's ability to develop products based on bacteriophages and synthetic phages to kill bacterial pathogens; the Company's expected market opportunity for its products; Armata's ability to sufficiently fund its operations as expected, including obtaining additional funding as needed; and any delays or adverse events within, or outside of, Armata's control, caused by the COVID-19 pandemic. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the SEC, including in Armata's Annual Report on Form 10-K, filed with the SEC on March 17, 2022, and in its subsequent filings with the SEC.


Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.






Media Contacts:


At Armata:

Pierre Kyme

Armata Pharmaceuticals, Inc.




Investor Relations:

Joyce Allaire

LifeSci Advisors, LLC








Armata Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
   June 30,
   December 31,
  Cash and cash equivalents  $36,978,000   $10,288,000 
  Awards receivable   1,883,000    2,989,000 
  Prepaids and other current assets   2,445,000    1,718,000 
Total current assets   41,306,000    14,995,000 
Property and equipment, net   38,277,000    38,072,000 
Other long term assets   7,655,000    2,955,000 
Intangible assets, net   13,746,000    13,746,000 
Total assets  $100,984,000   $69,768,000 
Liabilities and stockholders’ equity          
Total current liabilities  $7,383,000   $4,814,000 
Long term liabilities   37,233,000    36,480,000 
Deferred tax liability   3,077,000    3,077,000 
Total liabilities   47,693,000    44,371,000 
Stockholders’ equity   53,291,000    25,397,000 
Total liabilities and stockholders’ equity  $100,984,000   $69,768,000 






Armata Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
   Three Months Ended June 30,   Six Months Ended June 30, 
   2022   2021   2022   2021 
   (Unaudited)   (Unaudited)   (Unaudited)   (Unaudited) 
Grant Revenue  $1,883,000   $1,168,000   $3,119,000    2,234,000 
Operating expenses:                    
Research and development  $9,020,000   $5,225,000   $17,048,000   $9,575,000 
General and administrative   2,083,000    2,139,000    4,066,000    4,290,000 
Total operating expenses   11,103,000    7,364,000    21,114,000    13,865,000 
Loss from operations   (9,220,000)   (6,196,000)   (17,995,000)   (11,631,000)
Other income (expense), net   5,000    2,000    6,000    (58,000)
Loss before income taxes and Net Loss  $(9,215,000)  $(6,194,000)  $(17,989,000)  $(11,689,000)
Net loss per share, basic and diluted  $(0.26)  $(0.25)  $(0.55)  $(0.52)
Weighted average shares outstanding, basic and diluted   35,999,642    24,762,818    32,517,416    22,622,477 






Armata Pharmaceuticals, Inc.
Condensed Consolidated Statements of Cash Flows
   Six Months Ended June 30, 
   2022   2021 
Operating activities:          
Net loss  $(17,989,000)  $(11,689,000)
Adjustments required to reconcile net loss to net cash used in operating activities:          
Stock-based compensation   1,442,000    1,749,000 
Depreciation   421,000    578,000 
Payment of accreted interest for deferred consideration for asset acquisition   -    (586,000)
Non-cash interest expense   -    62,000 
Changes in operating assets and liabilities, net   4,463,000    (127,000)
Net cash used in operating activities   (11,663,000)   (10,013,000)
Investing activities:          
Purchases of property and equipment, net   (1,372,000)   (494,000)
Net cash used in investing activities   (1,372,000)   (494,000)
Financing activities:          
Payment of deferred consideration for asset acquisition   -    (1,414,000)
Proceeds from sale of common stock, net of offering costs   44,414,000    19,363,000 
Proceeds from exercise of warrants and stock options   71,000    445,000 
Net cash provided by (used in) financing activities   44,485,000    18,394,000 
Net increase (decrease) in cash and cash equivalents   31,450,000    7,887,000 
Cash, cash equivalents and restricted cash, beginning of period   11,488,000    10,849,000 
Cash, cash equivalents and restricted cash, end of period  $42,938,000   $18,736,000 


Reconciliation of Cash and cash equivalents:  Six Months Ended June 30, 
   2022   2021 
Cash and cash equivalents  $36,978,000   $17,536,000 
Restricted cash   5,960,000    1,200,000 
Cash, cash equivalents and restricted cash  $42,938,000   $18,736,000 




EX-101.SCH 3 armp-20220811.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 armp-20220811_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 armp-20220811_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2223185d1_ex99-1img001.jpg GRAPHIC begin 644 tm2223185d1_ex99-1img001.jpg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htm IDEA: XBRL DOCUMENT v3.22.2
Aug. 11, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 11, 2022
Entity File Number 001-37544
Entity Central Index Key 0000921114
Entity Tax Identification Number 91-1549568
Entity Incorporation, State or Country Code WA
Entity Address, Address Line One 4503 Glencoe Avenue
Entity Address, City or Town Marina del Rey
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90292
City Area Code 310
Local Phone Number 655-2928
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ARMP
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
XML 8 tm2223185d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000921114 2022-08-11 2022-08-11 iso4217:USD shares iso4217:USD shares 0000921114 false 8-K 2022-08-11 ARMATA PHARMACEUTICALS, INC. WA 001-37544 91-1549568 4503 Glencoe Avenue Marina del Rey CA 90292 310 655-2928 false false false false false Common Stock ARMP NYSEAMER EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://armatapharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2223185d1_8k.htm armp-20220811.xsd armp-20220811_lab.xml armp-20220811_pre.xml tm2223185d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2223185d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2223185d1_8k.htm" ] }, "labelLink": { "local": [ "armp-20220811_lab.xml" ] }, "presentationLink": { "local": [ "armp-20220811_pre.xml" ] }, "schema": { "local": [ "armp-20220811.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "armp", "nsuri": "http://armatapharma.com/20220811", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2223185d1_8k.htm", "contextRef": "From2022-08-11to2022-08-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://armatapharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2223185d1_8k.htm", "contextRef": "From2022-08-11to2022-08-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://armatapharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-089351-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-089351-xbrl.zip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end